.jpg)
STAT+: GSK CEO on pharma giant’s new direction: ‘We’re in the business of preventing and treating disease’
The story of GSK is one of reinvention, CEO Emma Walmsley said at the STAT…
Category: Pharma
What if there’s no market for a CRISPR cure?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Pfizer prices Paxlovid at $1,400 for a five-day course; EMA warns of counterfeit Ozempic
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award
Back in the 1990s, scientist Lotte Bjerre Knudsen was tasked with revitalizing a floundering program…
Wegovy doesn’t work for everyone, and no one’s quite sure why
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Opinion: STAT+: Preventive drugs may be the best solution to the antibiotic resistance crisis
The antibiotics crisis is a silent pandemic that threatens to knock modern society back into…
As Pfizer slashes revenue projections, Moderna says it “remains comfortable”
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: People with obesity harmed by exclusion from studies; Teva sues Colorado over ‘unconstitutional’ program
Rise and shine, everyone, another busy day is on the way. We can tell, in…
STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies
DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and…
STAT+: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab…
STAT+: Teva sues Colorado over ‘unconstitutional’ program to lower cost of epinephrine injectors
In the latest tussle over the cost of medicines, Teva Pharmaceuticals has filed a lawsuit…
Candor on gene therapy, Abiomed is warned, & BTK success in MS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Rite Aid files for bankruptcy; Alzheimer’s brain scans get broader Medicare coverage
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Eye docs urge Medicare to lower insurance hurdles amid shortage of repackaged Avastin
Due to a shortage of a widely used compounded medicine for serious eye diseases, two…
Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Makers of toxic cough syrups face new actions; Cassava suffers new blow over Alzheimer’s drug
And so, another working week will soon draw to a close. Not a moment too…
Cell and gene therapies could be a safer bet than other drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail
Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to…
STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer
A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine…
STAT+: Medicare may plan to negotiate drug prices, but some states are taking their own steps to lower costs
Anticipation may be high that Medicare can wring lower prices out of drugmakers, but a…
With Ozempic, Wall Street moves on from a whole other class of medicines
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
Want a biotech buyout? Target cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024
Hello, everyone, and nice to see you again. We have returned from an extended weekend…
STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion
Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug…
STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy
In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a compound…
NIH funds expanded access projects for ALS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages
Rise and shine, another busy day is on the way. We can tell because the…
Scientists want to put carbon footprints on drugs. But it’s hard to get accurate numbers
Anyone picking up a prescription from their pharmacy is used to the reams of paper…
STAT+: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?
Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug…
.jpg)
STAT+: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases
Several cases of sepsis — three of which ended in patients deaths — were traced…
The major biotech news updates you need to read today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA finds ‘potential systemic bias’ in Amgen cancer drug trial; drugmakers organize to push back on antitrust reviews
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
In the latest battle over access to medicines, Colombian authorities have decided to issue a…
When is a Wall Street disappointment ‘good enough’ for the FDA?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Drugmakers agree to negotiate Medicare prices under protest; AstraZeneca settles lawsuits over heartburn drugs
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: Court strikes down Trump-era rule that allowed health insurers to broadly use copay accumulators
A U.S. judge has struck down a Trump administration rule that allowed health insurers not…
STAT+: Pharmalittle: Court allows Medicare drug price negotiation to proceed; J&J will not enforce patents on key TB drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: J&J agrees not to enforce patents on a key tuberculosis drug in dozens of poor countries
In an unexpected turnabout, Johnson & Johnson announced it would not enforce any of its…
STAT+: Court allows Medicare drug price negotiation to proceed
WASHINGTON — A federal court judge allowed a new Medicare drug price negotiation program to…
STAT+: Unitaid slams J&J over pricing and patents for a tuberculosis drug
In a highly unusual move, Unitaid has publicly criticized Johnson & Johnson over its pricing…
STAT+: Generic makers fall short when providing access to low- and middle-income countries, analysis finds
A handful of the largest purveyors of generic medicines have made only halting progress to…
STAT+: Sales from controversial drug discount program rose to $54 billion last year
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $53.7…
STAT+: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals
And so, another working week will soon draw to a close. Not a moment too…
STAT+: GOP senator probes drug discount programs at Cleveland Clinic, Bon Secours
WASHINGTON — The top ranking Republican on the Senate health committee is launching an investigation…
STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments
Ophthalmologists who accepted payments from drug companies were less likely to prescribe a cheaper medicine…
STAT+: Pharmalittle: FDA advisers vote overwhelmingly against ALS treatment; weight-loss drugs scrutinized over reports of suicidal thoughts
Top of the morning to you, and a fine one it is. Despite overcast skies,…
STAT+: 6 ways the government could help address drug shortages, including in cancer
WASHINGTON — Republicans and Democrats alike want to stop drug shortages from happening. The vexing…